{"id":"W4387824903","doi":"10.1016/j.annonc.2023.09.1436","title":"1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Cilag; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; INCLIVA Instituto de Investigación Sanitaria; Deutschen Konsortium für Translationale Krebsforschung; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; HORIZON EUROPE Framework Programme; Servier; Astellas Pharma; Universidad de Navarra; Seoul National University Hospital; Fundación Científica Asociación Española Contra el Cáncer; Sanofi; Sungkyunkwan University; Pfizer; Incyte; Yonsei University; Seagen; BeiGene; University of Seoul; Cancer Research UK; Azərbaycan Milli Elmlər Akademiyası; Mirati Therapeutics; F. Hoffmann-La Roche; National Cancer Center Japan; Les Laboratories Pierre Fabre; Array BioPharma; Taiho Pharmaceutical; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Oncode Institute; American Society of Clinical Oncology; Merck; Universitat de Barcelona; Amgen; Celgene","keywords":"Ramucirumab; Medicine; Paclitaxel; Trastuzumab; Internal medicine; Oncology; Cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00181988,0.001169495,0.001959242,0.0004136285,0.0003574074,0.001496183,0.001164997,0.001141352,0.005345614],"category_scores_gemma":[0.00114662,0.0005402025,0.002075213,0.0004918355,0.000796487,0.0008557123,0.0004001174,0.003570331,0.001316891],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001268648,"about_ca_system_score_gemma":0.001675052,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002453017,"about_ca_topic_score_gemma":0.005513916,"domain_scores_codex":[0.9995127,0.0002568561,0.00001727064,0.00007261435,0.00004997403,0.00009066524],"domain_scores_gemma":[0.9994215,0.0001046321,0.0001107013,0.00006594039,0.00004045806,0.0002567707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7006499,0.04780484,0.008384185,0.0007626633,0.004139953,0.0002617484,0.0004279681,0.009861551,0.04358619,0.000818171,0.01634038,0.1669625],"study_design_scores_gemma":[0.6462674,0.306018,0.02426737,0.00006267039,0.001936249,0.0005314161,0.0001468969,0.004083481,0.005124364,0.0005096552,0.01097136,0.00008110429],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891089,0.001968897,0.0006461897,0.0007144453,0.0001059698,0.00112083,0.002803562,0.0002044376,0.003326775],"genre_scores_gemma":[0.979997,0.001930991,0.003079445,0.001418178,0.0001400729,0.001395247,0.006976164,0.0001714202,0.004891429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005345614,"threshold_uncertainty_score":0.01788288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1139977458540278,"score_gpt":0.4384518013909765,"score_spread":0.3244540555369487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}